Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 |
您所在的位置：网站首页 › epocal › Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 |
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010
|
DUBLIN , April 7, 2023 /PRNewswire/ -- The "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023" report has been added to ResearchAndMarkets.com's offering. The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2023.The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010, including a summary of the recent literature on the subject.Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal. The chapter includes numerous case studies for actual deals where royalty rates have been disclosed.Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates, and why.Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.In addition the report includes a comprehensive appendix listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010.In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.Key benefits Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 provides the reader with the following key benefits: In-depth understanding of royalty rate partnering deal trends since 2010 Analysis of the structure of royalty clauses with real life case studies Comprehensive listing of all partnering deals since 2010 where a royalty rate is disclosed, together with deal terms, value and press release Comprehensive access to actual partnering deal contracts entered into by the world's life science companies where a royalty rate is disclosed Insight into the royalty terms included in a licensing agreement, together with real world clause examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companiesReport scopeGlobal Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 includes: Trends in royalty rates in the biopharma industry since 2010 Analysis of the structure of royalty clauses with real life case studies Comprehensive listing of licensing deals which disclose royalty rates since 2010 Access to licensing contract documents which disclose royalty rates The leading licensing deals by royalty rate value since 2010 Most active royalty rate disclosures since 2010In Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 available deals and contracts are listed by: Company A-Z Headline value Therapeutic area Technology typeEach deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023 report provides comprehensive access to available contract documents for licensing deals.Analyzing actual contract agreements allows assessment of the following: What are the precise royalty rates granted? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law?Companies Mentioned 3D Medicines Abbott Laboratories Abbvie Ablynx Abraxis BioScience Acceleron Pharma Acerus Actavis (acquired by Watson) Active Biomaterials Acura Pharmaceuticals Adamis Pharmaceuticals Adaptimmune Adeona Pharmaceuticals Adlai Nortye Aduro BioTech Advanced Dosage Forms Advaxis Advirna Aegerion Pharmaceutical AEterna Zentaris Afritex Medical Products Agenus Bio Agios Pharmaceuticals AIT Therapeutics Akcea Therapeutics Akebia Therapeutics Alchemia Alder Biopharmaceuticals Alector Alexion Pharmaceuticals Alexza Pharmaceuticals Alfasigma Alfa Wassermann Allergan Allergan (name changed from Actavis) Almirall Alnylam Pharmaceuticals Alternavida Altman Enterprises AltrazealTrading Amarantus BioSciences American Type Culture Collection (ATCC) Amgen Amherst Pharmaceuticals Amorfix Life Sciences Ampio Pharmaceuticals Amylin Pharmaceuticals Amyris AnaBios AnGes MG AnnaMed Antibe Therapeutics Antigen Express Apricus Biosciences Aquestive Therapeutics Aradigm Aratana Therapeutics Arch Pharmalabs Ardelyx Arena Pharmaceuticals Assembly Biosciences Astellas Pharma Astellas Pharma Europe Asterias Biotherapeutics AstraZeneca Athenex Atossa Genetics Audeo Oncology Aurigene Discovery Technologies Authentic Brands Group AVEO Oncology Avita Medical Avivagen Axovant Sciences Aytu BioScience Azaya Therapeutics Azure Biotech Baker Brothers Investments BASF Baxter International Bayer Healthcare Bayer Innovation Baylor Research Institute Belgian Volition Bellerophon Therapeutics Benitec Biopharma Besins Healthcare Beth Israel Deaconess Medical Center BIND Biosciences BioCorRx BioCryst Pharmaceuticals Bioeq IP Biogen BioGene Technology BioInvent BiolineRX BioMarin Pharmaceutical BioNovion BioNTech Biopharmex BiopharmX BioPorto Bioprocess Capital Ventures BioProspect Biostem US Biotech Investment Biotechnology Value Fund BioTime Acquisition Bioton Biovail BioZone Laboratories BioZone Pharmaceuticals Bluebird Bio BMV Medica Boehringer Ingelheim Braeburn Pharmaceuticals BrainStorm Cell Therapeutics Breathtec BioMedical Bristol-Myers Squibb Caleco Pharma Calico Can-Fite BioPharma Cancer Prevention Pharmaceuticals CanniMed Therapeutics Canntab Therapeutics Cannus Partners Cantex Pharmaceuticals Cardigant Medical Cardium Therapeutics CareFusion Cary Pharmaceuticals Castle Creek Pharmaceuticals Catalent CB2 Therapeutics Celdara Medical Celgene Cell Cure Neurosciences Cel Sci Celyad Cereal Ingredients Cerus cGreen Chi-Med Chiesi Farmaceutici Chimerix Chong Kun Dang Chongqing Jingdong Pharmaceutical Cimtech Cipher Pharmaceuticals Cipla Circassia Clal Biotech Clalit Health Services Clemson University Cleveland BioLabs Clinigen CMIC CNS Pharmaceuticals Cocrystal Pharma Coeptis Pharmaceuticals Cohen-McNiece Foundation Coherus Biosciences Colby Pharmaceuticals Columbia Laboratories Columbia University Common Sense Concile ContraFect Coronado Biosciences CRISPR Therapeutics Crucell CTT Pharmaceutical Cumberland Pharmaceuticals Cures Within Reach CureTech Curis Currax Pharmaceuticals CURx Pharmaceuticals Cutanea Life Sciences Cypress Bioscience Cytodyn Cytori Therapeutics Daewoong Pharmaceutical Daiichi Sankyo Dana-Farber Cancer Institute Dance Biopharm DAS Therapeutics Defiante Farmaceutica Denali Therapeutics Derma Sciences Dermin Dianomi Therapeutics Dicerna Pharmaceuticals DNA Biomedical Solutions Dr. Falk Pharma Dr. Reddy's Laboratories Drugs for Neglected Diseases Initiative DS Healthcare Duke University Dyax Eagle Pharmaceuticals Eagle Pharmaceuticals (US) Easton Pharmaceuticals Echo Therapeutics Ecology Coatings Eddingpharm Egalet Eisai Elencee Eli Lilly Elite Pharmaceuticals Emergent BioSolutions Emory University Endocyte Endo Pharmaceuticals Enochian Biosciences Entera Bio Entest BioMedical EnWave Epizyme Epocal Esperion Therapeutics Eternity Healthcare Eureka Genomics EUSA Pharma Evolva Exact Sciences Exelixis Eyevance Fairview Health System FasTrack Pharmaceuticals Fibrocell Science Fibrogen Forest Laboratories Fosun Pharmaceutical Fresenius Kabi Pharmaceuticals FSD Pharma FusionVax Galapagos Galmed Pharmaceuticals Genentech Generex Biotechnology Genevant Sciences Genmab Gentium Genzyme Geron Gilead Sciences GlaxoSmithKline Glenmark Generics Inc USA Glenmark Pharmaceuticals Goldfinch Bio Government of Israel Gravocore Grifols GT Biopharma Hail First Pharma Hainan Sihuan Pharmaceutical Halo Labs Halozyme Therapeutics Hansen Medical Health Canada Health Discovery Heat Biologics Hefei Life Science Hefei Tianhui Incubation of Technologies HemoCleanse Hemogenyx HemPup HIBM Research Group Hikma Pharmaceuticals Hoffmann La Roche Hollister Biosciences Hookipa Pharma Horizon Pharma Inc HyperGenomics Icahn School of Medicine at Mount Sinai Ice + Jam IDC-GP Pharm Idera Pharmaceuticals Idorsia iMetabolic Biopharma Immugenyx Immunomic Immunovative Therapies Impax Laboratories Imprimis Pharmaceuticals iNAP Incuron Incyte Infinity Pharmaceuticals Inhibitor Therapeutics Innate Pharma Innocoll Innovation Pharmaceuticals Innovus Pharmaceuticals INO Therapeutics Inspiration Biopharmaceuticals Instrumentation Laboratory IntelGenx IntelliCell BioSciences Intellikine Internet Marketing Consortium Intrexon Intuitive Surgical Invekra Inverness Medical Innovations Ionis Pharmaceuticals Ipsen Ironwood Pharmaceuticals Israeli National Authority for Technological Innovation Jaguar Health Janssen Biotech Janssen Pharmaceuticals Jazz Pharmaceuticals JFC Technologies Jiangsu Alphamab Jiangsu Lianhuan Pharmaceuticals Jiangsu NHWA Pharmaceutical John Morley Foods Juniper Pharmaceuticals K2M Kadmon Pharmaceuticals KaloBios Pharmaceuticals KemPharm Kensey Nash Kieran Murphy Kinetic Concepts Kiniksa Pharmaceuticals Kitov Klaria Knighton Foods Knight Therapeutics Kodiak Sciences Kraig Biocraft Laboratories KVK-Tech Kwang Dong Pharmaceutical Kyowa Hakko Kirin Laboratories Acbel Legend Biotech Level Brands LFB Biotechnologies Lifestyle Delivery Systems Ligand Pharmaceuticals Lubrizol Lumenis Lundbeck MabCure Macrogenics Magenta Therapeutics MainPointe Mallinckrodt Pharmaceuticals Marvanal Marv Enterprises Massachusetts General Hospital Mayne Pharma McComb Foundation McEwen Centre for Regenerative Medicine Meda Medica Medica Avante Medical Technologies Innovation Asia Medicines Patent Pool Foundation MediGene MedImmune Medison Pharma Medivation Medivir Medovex Melmed Memory Dx Merck and Co Merck KGaA Merck Serono Merus Micromet Mikah Pharma Millennium Mimi's Rock Ministry of Health Labor and Welfare Miraculins Moderna Therapeutics Moleculin Biotech Mologen Morgan Stanley MorphoSys MultiCell Immunotherapeutics Munich Leukemia Laboratory NantCell Nantong Jinghua Pharmaceutical NantWorks Napo Pharmaceuticals Natac Biotech Natco Pharmaceuticals National Green Biomed Nektar Therapeutics Neogenomics Nephrogenex Nephros Neurocrine Biosciences NeuroSigma NeuroVive Pharmaceutical NeuroVive Pharmaceutical Asia NewLeaf Brands Newsoara Biopharma New York University NexMed Nextleaf Solutions Nexvet NGM Biopharmaceuticals Nicox Nordic Bioscience Norgine Notable Labs Novadaq Technologies NovaDel Pharma Novan Novan Therapeutics Novartis Novartis Vaccines and Diagnostics Novocure Novus Biologicals Nucorion Nurix Nutech Medical NutraOrigin NXTGEN Nymox Pharmaceutical Oberland Capital Oculus Innovative Sciences Ocumension Therapeutics Omeros Oncologie Oncolytics Biotech OncoMed Pharmaceuticals Onegevity One Way Liver Genomics (OWL) Onyx Pharmaceuticals Opexa Therapeutics OptiBiotix OptiNose Oragenics Oramed Pharmaceuticals Orexigen Therapeutics Organovo Orgenesis Orion Orox Pharmaceuticals OrthoCyte Otsuka OvaMed Oxford BioMedica Oxis Biotech Oxygen Biotherapeutics OxySure Systems Pan-Provincial Vaccine Enterprise Parnell Pharmaceutical Holdings Par Pharmaceutical PDL BioPharma Penwest Pharmaceuticals Pernix Therapeutics Perugia University Pfizer Pharmacyclics PharmaMar PharmaNova Pharmastrip Phosphagenics Phusion Laboratoies Phyto Nutricare Pieris Pipex Pharmaceuticals Plandai Biotechnology Pluristem Therapeutics Portola Pharmaceuticals Poseida Therapeutics Pozen PreMD Premier Biomedical Professional Compounding Centers of America Progenics Pharmaceuticals Prometic Life Sciences ProQR Therapeutics Prosidion Protalix BioTherapeutics Proteonomix Prothena Biosciences ProtoKinetix Pulmatrix Puma Biotechnology QRxPharma Quick Med Technologies Quigley Corporation Reata Pharmaceuticals Recordati Recro Pharma RedHill Biopharma Reedy Creek Investments RegenaStem Regeneron Pharmaceuticals Relmada Therapeutics ReNeuron Resarci Therapeutics Retrophin rEVO Biologics Revolution Medicines Rigel Pharmaceuticals RNL Bio Roche Rockefeller University Roivant Sciences Royalty Pharma RST Biomedikal Sanayi Ruthigen RXi Pharmaceuticals S2 Therapeutics SACCO Sage Therapeutics Salix Pharmaceuticals Sam Amer Sandoz Sanofi Sanofi-Aventis Sanofi-Pasteur Santarus Santen Pharmaceutical SA Pathology Sarepta Therapeutics Seattle Genetics Seelos Therapeutics Senetek Sermonix Pharmaceutical Sheba Medical Center Shenzhen BioScien Pharmaceuticals Shield Therapeutics Shionogi Shire Pharmaceuticals Shore Therapeutics Sigma-Tau Sinclair Pharmaceuticals Sinobiopharma Sinopharm Skinvera Skyline Diagnostics Solarvest BioEnergy Soliance Soligenix Sorrento Therapeutics Spectranetics Spencer Pharmaceutical Spinal USA St. Jude Children's Research Hospital STADA Arzneimittel Stealth Therapeutics Stellar Biotechnologies St Jude Medical Strongbridge Biopharma Sucampo AG Sunesis Pharmaceuticals SuperNova Diagnostics Swedish Orphan Biovitrum Symbollon Synergy Strips Syntopix Tactical Relief Taiba Takeda Pharmaceutical Tango Therapeutics Target Group Tauriga Sciences TB Alliance Technion Research and Development Foundation Tetra Bio-Pharma TetraLogic Pharmaceuticals Teva Pharmaceutical Industries Texas A&M University Therakine Theravance Theravance Biopharma The Regents of the University of California Thorne Research Threshold Pharmaceuticals TiGenix Tilray Titterington Veterinary Services Tiziana Life Sciences TONIX Pharmaceuticals Torii Pharmaceutical TRACON Pharmaceuticals Tramorgan Transgene Trellis Bioscience Trevena Trimedyne Trimeris TrovaGene TTFactor Turnstone Biologics Tyme Technologies Ultragenyx Pharmaceuticals Uluru Unigene Laboratories UniQure Universal Cells University Health Network University of Alberta University of California University of Central Florida Research Foundation University of Colorado University of Florida Research Foundation University of Geneva University of Missouri University of Notre of Dame University of Pennsylvania University of Western Sydney University of Zurich UOP Uppsalagruppen Medical Upstream Peripheral Technologies UroGen Pharma Valeant Pharmaceuticals ValiPharma Valor Biotherapeutics Vanderbilt University Vasomune Therapeutics Vaxent VBL Therapeutics (dba) Veloxis Pharmaceuticals Veracyte Verenium VeroScience Vertex Pharmaceuticals Vida Concepts ViiV Healthcare Virbac Viropharma VistaGen Therapeutics Vividion Therapeutics VolitionRX Voyager Therapeutics Vyera Pharmaceuticals Vyrix Pharmaceuticals Watson Pharmaceuticals WAVE Life Sciences Wisconsin Alumni Research Foundation World Class Extractions WPD Pharmaceuticals Xbrane Bioscience Xencor XTL Biopharmaceuticals Xynomic Pharmaceuticals Yale University Yeda Research and Development Company Yeugnam University ZAI Laboratory Zalicus Zenitech Zenith Epigenetics Ziopharm Oncology ZS PharmaFor more information about this report visit https://www.researchandmarkets.com/r/4j3g2b About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and MarketsLaura Wood, Senior Manager[email protected] For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg SOURCE Research and Markets 
|
【本文地址】